Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

BACKGROUND: Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety has not been established for administration of MSCs in critically ill patients with ARDS. We did a phase 2a trial to assess s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Respir Med
Main Authors: Matthay, Michael A, Calfee, Carolyn S, Zhuo, Hanjing, Thompson, B Taylor, Wilson, Jennifer G, Levitt, Joseph E, Rogers, Angela J, Gotts, Jeffrey E, Wiener-Kronish, Jeanine P, Bajwa, Ednan K, Donahoe, Michael P, McVerry, Bryan J, Ortiz, Luis A, Exline, Matthew, Christman, John W, Abbott, Jason, Delucchi, Kevin L, Caballero, Lizette, McMillan, Melanie, McKenna, David H, Liu, Kathleen D
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7597675/
https://ncbi.nlm.nih.gov/pubmed/30455077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(18)30418-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados